Cipla Ltd recorded its highest ever revenue of ₹28,000 crore for the financial year ended March 31, 2026, driven by strong performance across key geographies including India and North America. The company achieved an EBITDA margin of 21% and a profit after tax margin of 13.8% during the year. Cipla maintained its position as the leading indigenous pharmaceutical company in volume terms in India, while its North America business delivered $780 million in revenue.

Financial Performance and Operational Highlights

The India business grew 9% year-on-year to cross ₹12,500 crore for the first time, supported by growth across prescription, generic, and consumer segments. In North America, the company continued to focus on complex products, including a generic Ventolin inhaler approved from its Fall River facility. The One Africa business reported $483 million in revenue, growing 7% and outpacing the market growth by 1.4 times. Emerging markets contributed over $400 million in revenue, extending the company's reach to patients in 80 countries.

Strategic Investments and Sustainability

Cipla strengthened its financial discipline, increasing its cash position from approximately ₹5,000 crore to ₹11,000 crore in FY 2026. The company invested 7% of its total revenue in research and development to fuel innovation and future pipeline growth. On the sustainability front, Cipla achieved an 82% reduction in Scope 1 and Scope 2 emissions over the last six years and attained 2.6 times water positivity. The company utilizes 84% renewable electricity across its facilities and has committed to a net-zero target by 2050.

Board Decisions and Auditor Appointment

The Board recommended a final dividend of ₹30 per equity share for FY26, payable within 30 days from the date of the Annual General Meeting. Shareholders approved the reappointment of Mr Adil Zainulbhai as a Director liable to retire by rotation. Additionally, the company appointed M/s B S R & Co. LLP as the statutory auditor for a term of five years, effective from the conclusion of the 90th Annual General Meeting, at a remuneration of ₹3.15 crores plus applicable taxes for FY27. The appointment follows the completion of the term by the previous auditor, M/s Walker Chandiok & Co. LLP.

Future Outlook and Growth Drivers

Management outlined a three-pillar strategy focusing on leadership in home markets, differentiated products in North America, and consolidation in Africa and emerging markets. The company plans to introduce more products in India, particularly in respiratory and chronic diseases like diabetes and cardiology. Cipla expects to file 40 to 50 products in the US over the next three years, with a focus on respiratory therapies, peptides, oligonucleotides, and biosimilars. The company is also adopting artificial intelligence initiatives to improve efficiency and decision-making.

Pharmaceutical company Cipla has announced that its board of directors is scheduled to meet on July 23 to consider the financial results for the first quarter.

Board Meeting Details

The upcoming board meeting represents a significant corporate milestone, as the company will review and consider its Q1 financial performance. The announcement signals the company's adherence to regulatory disclosure timelines for quarterly results.

Stakeholders and market participants are expected to closely track the outcome of the board meeting, as the Q1 results will provide insight into the company's financial performance for the quarter.